Objective: To investigate the effect of endostatin combined with pemetrexed and cisplatin on the levels of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma. Methods: The retrosp...Objective: To investigate the effect of endostatin combined with pemetrexed and cisplatin on the levels of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma. Methods: The retrospective analysis method was used to analyse the 80 patients with advanced adenocarcinoma of the lung in our hospital from January 2013 to January 2017, and patients were divided into two groups: the control group and the observation group. The patients in the control group received pemetrexed combined with cisplatin on the basis of conventional treatment, the observation group was treated with endostatin on the basis of the treatment of the control group, then the changes of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 levels in two groups before and after treatment (3 cycles of chemotherapy) were detected and compared. Results: Before treatment, there was no significant difference in serum TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 levels between the two groups;After treatment, the levels of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in the control group were (5.58±2.43) pg/mL, (17.65±6.97) ng/mL, (6.13±1.14) ng/mL, (62.48±7.86) U/mL, (15.28±4.17) ng/mL, (2.81±0.54) ng/mL, that in the observation group were (4.37±2.15) pg/mL, (11.33±5.24) ng/mL, (4.65±0.88) ng/mL, (51.71±5.23) U/mL, (10.29±3.56) ng/mL, (1.74±0.23) ng/mL, Compared with the same group before treatment, the level of indicators were significantly improved, the difference was statistically significant, and The improvement of the indexes in the observation group was obviously better than that in the control group, and the difference was statistically significant. Conclusion: With the use of pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma patients, the addition of endostatin could improve the levels of serum TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma, To some extent, it shows that the combined use of drugs is more effective and is worthy of further clinical research and application.展开更多
文摘Objective: To investigate the effect of endostatin combined with pemetrexed and cisplatin on the levels of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma. Methods: The retrospective analysis method was used to analyse the 80 patients with advanced adenocarcinoma of the lung in our hospital from January 2013 to January 2017, and patients were divided into two groups: the control group and the observation group. The patients in the control group received pemetrexed combined with cisplatin on the basis of conventional treatment, the observation group was treated with endostatin on the basis of the treatment of the control group, then the changes of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 levels in two groups before and after treatment (3 cycles of chemotherapy) were detected and compared. Results: Before treatment, there was no significant difference in serum TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 levels between the two groups;After treatment, the levels of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in the control group were (5.58±2.43) pg/mL, (17.65±6.97) ng/mL, (6.13±1.14) ng/mL, (62.48±7.86) U/mL, (15.28±4.17) ng/mL, (2.81±0.54) ng/mL, that in the observation group were (4.37±2.15) pg/mL, (11.33±5.24) ng/mL, (4.65±0.88) ng/mL, (51.71±5.23) U/mL, (10.29±3.56) ng/mL, (1.74±0.23) ng/mL, Compared with the same group before treatment, the level of indicators were significantly improved, the difference was statistically significant, and The improvement of the indexes in the observation group was obviously better than that in the control group, and the difference was statistically significant. Conclusion: With the use of pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma patients, the addition of endostatin could improve the levels of serum TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma, To some extent, it shows that the combined use of drugs is more effective and is worthy of further clinical research and application.
